12/16/2021, 3:09 PM (Source: TeleTrader)
more TeleTrader news

EMA approves GSK's COVID-19 treatment

The European Medicines Agency (EMA) authorized on Thursday the use of the monoclonal antibody Xevudy (sotrovimab) for the treatment of COVID-19 in people aged 12 and over, who are at risk of serious illness. The drug is made by GlaxoSmithKline Trading Services Ltd. with Vir Biotechnology.

EMA evaluated data from a study involving 1,057 patients with COVID-19 that showed 1% of treated patients were hospitalized for longer than 24 hours within 29 days of treatment, compared with 6% of patients on placebo. The drug is also expected to be active against the Omicron variant, the agency stated.

Baha Breaking News (BBN) / DJ